FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 1001 - President's Cancer Panel - Statutory (Congress Created)

GENERAL INFORMATION

Committee Name	President's Cancer Panel	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	1001
Original Establishment Date	11/20/1985	Committee Status	Chartered
Actual Termination Date		Committee URL	https://prescancerpanel.cancer.gov/
Actual Merged Date		Presidential Appointments*	Yes
New Committee This FY	No	Max Number of Members*	3
Terminated This FY	No	Designated Fed Officer Position Title*	Senior Health Science Policy Advisor
Merged This FY		Designated Federal Officer Prefix
Current Charter Date	5/31/2024	Designated Federal Officer First Name*	SAMANTHA
Date Of Renewal Charter	5/31/2026	Designated Federal Officer Middle Name	L.
Projected Termination Date		Designated Federal Officer Last Name*	FINSTAD
Exempt From Renewal*	No	Designated Federal Officer Suffix	Ph.D.
Specific Termination Authority		Designated Federal Officer Phone*	(240) 276-6460
Establishment Authority*	Statutory (Congress Created)	Designated Federal Officer Fax*	(240) 541-4505
Specific Establishment Authority*	42 U.S.C. 285a-4	Designated Federal Officer Email*	samantha.finstad@nih.gov
Effective Date Of Authority*	11/20/1985
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	Yes
Committee Function*	National Policy Issue Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Continue
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	The committee is composed of three members who provide advice and recommendations to the President of the United States in the areas of policy, health care, research, and information dissemination. The Panel monitors the development and execution of the activities of the National Cancer Program. Any delays or blockages in rapid execution of the Program are immediately brought to the attention of the President. The Panel conducts meetings throughout the country that serve as a forum for the scientific community and for the public. Based on expert testimony presented and discussions occurring at these meetings, the Panel makes recommendations, some of which have affected the efforts of the White House and initiation of new NCI programs and the implementation of existing priorities. A series of meetings were held in FY24 regarding reducing cancer care inequities through leveraging technology to enhance patient navigation. This topic aligns with and supports two of the eight National Cancer Plan goals: to Eliminate Inequities and to Deliver Optimal Care. The President’s Cancer Panel will prospectively assess the needs related to these goals, focusing on gaps and opportunities related to the use of technology to support cancer patient navigation. The series of meetings was focused on opportunities for enhancing patient navigation (October 17, 2023); technology opportunities for patient navigation (November 2-3, 2023); and policy considerations at the intersection of technology and patient navigation (December 7, 2023). In addition, a virtual meeting was held on September 12-13, 2024, to gather information from stakeholders regarding activities addressing goal 8 (Optimize the Workforce) of the National Cancer Plan specifically on challenges and opportunities for the cancer care and research workforce.
How is membership balanced?*	The President's Cancer Panel consists of three persons appointed by the President, who by virtue of their training, experience and background, are exceptionally qualified to appraise the National Cancer Program. It is mandated that at least two of the members of the Panel will be distinguished scientists or physicians.
How frequent & relevant are cmte mtgs?*	Meetings are generally held not less than four times each fiscal year at the call of the Chair. The Panel met four times during FY24. Virtual meetings were held on November 2-3, 2023 and September 12-13, 2024 and hybrid meetings were held on October 17, 2023 and December 7, 2023.
Why advice can't be obtained elsewhere?*	The President's Cancer Panel was established by law, and the chairman submits to the President, the Secretary, and the Congress an annual evaluation of the National Cancer Program and suggestions for improvements. The Panel also submits such other reports as the White House requests. The quality, scope, and balance of advice from this Panel cannot be obtained from NIH staff or from other established sources because the membership of the Panel is constituted to meet the specific requirements of its mandated mission to appraise the National Cancer Program.
Why close or partially close meetings?	N/A
Recommendation Remarks	Max Number of Members Total: The Charter allows the Committee to have 3 authorized members, which is the total number of members permitted. Members Rotating Off/On-Boarding: Dr. Elizabeth Jaffee was terminated on 3/8/2025 and no member was on-boarded. The Charter states 3 members and this ACR lists 3. Members: The term for Dr. Elizabeth Jaffee changed due to termination. As such, her term of service end date is different than what was reported on the FY24 ACR. Reports: The Designated Federal Official (DFO) and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	Yes
Outcome Trust In Government	Yes	Action Reallocate Resources	No
Outcome Major Policy Changes	Yes	Action Issued New Regulations	No
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	Yes	Action Other	No
Outcome Increased Customer Satisfaction	Yes	Action Comment	N/A
Outcome Implement Laws/Reg Requirements	Yes	Grants Review*	No
Outcome Other	No	Number Of Grants Reviewed	0
Outcome Comment	The PCP, because it is charged under the Cancer Act to assess the program, has indicated that it has responsibilities in all areas of the cancer program which includes the above.	Number Of Grants Recommended	0
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	NIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.	Grants Review Comment	N/A
Number Of Recommendations*	216	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	There were 12 recommendations made in the "The President’s Cancer Panel Initial Assessment of the National Cancer Plan" report.	Access Agency Website	Yes
% of Recs Fully Implemented*	0.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	Due to the large breadth and complexity of the recommendations made by this committee, NCI staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	0.00%	Access Publications	Yes
% of Recs Partially Implemented Comment	Due to the large breadth and complexity of the recommendations made by this committee, NCI staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.	Access Other	Yes
Agency Feedback*	Yes	Access Comment	Information on the PCP can be found at the President’s Cancer Panel website at https://prescancerpanel.cancer.gov. Findings are also communicated through mailings and in person briefings.
Agency Feedback Comment*	Information is provided to the public at each meeting. The public can view information related to the Committee through the committee’s official website.	Narrative Description*	NIH’s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The President’s Cancer Panel was established under the authorities of the National Cancer Act of 1971, to monitor the development and execution of the activities of the National Cancer Program (the Program) and report annually to the President on any delays or blockages in the rapid execution of the Program. Annual identification and assessment of the issues facing the National Cancer Program contribute to the advancement of this mission and the development of the NIH strategic plan in regards to cancer. Over its approximately 53 year history, the Panel has engaged in active dialogue with all participants in the Program in an effort to assess the progress and coordination of the Program. The Panel has generally held four or more meetings in each series to gather information and to stimulate discussion among prominent scientists, clinicians, academia, business, industry and the government. Recent topics have included opportunities for leveraging technology to enhance patient navigation; optimizing the cancer workforce; closing gaps in cancer screening by connecting people, communities, and systems to improve equity and access; how to increase the uptake of the human papillomavirus (HPV) vaccine; the potential for connected health strategies and technologies to engage and activate individuals and patients, with the ultimate goal of improving cancer-related outcomes; ensuring patients' access to high-value cancer care; and accessing and improving cancer screening drugs. As a link between the President and the public on cancer issues, the Panel provides information that informs cancer policy at the Executive level through its mandate to assess the efficacy of the National Cancer Program. The meetings of the Panel present a unique opportunity to identify and bring together the vast research, health care and manpower resources of this Nation by eliciting public testimony in assessment of the National Cancer Program. The PCP meetings provide the President with the means to identify both the strengths and the weaknesses of the National Cancer Program and the opportunity to seek out needed adjustments. The Panel fills a critical need as the sometimes costly screening, treatment, and technological advances made possible through cancer research must be successfully and equitably applied throughout the country to alleviate suffering and death caused by cancer.

COSTS

1. Payments to Non-Federal Members*		1. Est Paymnts to Non-Fed Membrs Nxt FY*
2. Payments to Federal Members*		2. Est. Payments to Fed Members Next FY*
3. Payments to Federal Staff*		3. Estimated Payments to Federal Staff*
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*
10. Other Costs		10. Est. Other Costs Next FY*
11. Total Costs	$0.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	3/14/2025 9:25 AM	Est. Fed Staff Support Next FY*
Federal Staff Support (FTE)*		Est Cost Remarks
Cost Remarks

Interest Areas

Category Area Health Treatment Medicine Diseases Health and Health Research

Custom Links

Committee Level Reports